Heteromer formation between cannabinoid type 1 and dopamine type 2 receptors is altered by combination cannabinoid and antipsychotic treatments

Medicine & Life Sciences

• Cannabinoids 100%
• Dopamine Receptors 97%
• Antipsychotic Agents 78%
• 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol 77%
• Dopamine 51%
• Olanzapine 44%
• Globus Pallidus 43%
• Haloperidol 40%
• 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol 20%
• Aminobutyrates 18%
• Cannabinoid Receptor Agonists 16%
• Cannabinoid Receptors 15%
• Inbred C57BL Mouse 11%
• Ligation 10%
• Cell Culture Techniques 9%
• Neurons 7%